Dicomit is an antiepileptic drug mainly used to treat Dravet syndrome and refractory epilepsy. It exerts therapeutic effects by regulating GABAergic neurotransmission and has been clinically proven to significantly reduce the frequency of epileptic seizures.

1. Basic information of the drug

(1) Common name: Streptopentanol

(2) Product Name: Diacomit

(3) Drug category: Antiepileptic drugs/Anticonvulsant drugs

2 Indications for Treatment

(1) Dravet syndrome: suitable for adjuvant treatment of epileptic seizures in patients aged 2 years and above.

(2) Refractory epilepsy: severe cases of epilepsy with poor response to traditional antiepileptic drugs.

3 Pharmacological mechanisms of action

(1) GABAergic regulation: enhances inhibitory neurotransmission mediated by gamma aminobutyric acid.

(2) Sodium channel effects: may stabilize neuronal electrical activity by inhibiting voltage dependent sodium channels.

4 Clinical efficacy characteristics

(1) Seizure control: Clinical trials have shown a significant reduction in seizures in patients with Dravet syndrome.

(2) Long term effect: Continuous treatment can maintain antiepileptic effects and improve patients' quality of life.